Search results for " neoplasms"

showing 6 items of 6106 documents

Antibacterial activity and cytotoxicity of selected Egyptian medicinal plants.

2011

Medicinal plants have been used as a source of remedies since ancient times in Egypt. The present study was designed to investigate the antibacterial activity and the cytotoxicity of the organic extracts from 16 selected medicinal plants of Egypt. The study was also extended to the isolation of the antiproliferative compound jaeschkeanadiol p-hydroxybenzoate (FH-25) from Ferula hermonis. The microbroth dilution was used to determine the minimal inhibitory concentration (MIC) of the samples against twelve bacterial strains belonging to four species, Providencia stuartii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli, while a resazurin assay was used to assess the cytoto…

ved/biology.organism_classification_rank.speciesPharmaceutical ScienceBreast NeoplasmsMicrobial Sensitivity TestsProvidenciamedicine.disease_causeAnalytical Chemistrychemistry.chemical_compoundMinimum inhibitory concentrationInhibitory Concentration 50MagnoliopsidaCell Line TumorKlebsiellaPseudomonasDrug DiscoverymedicineEscherichia coliHumansVitisCytotoxicityMedicinal plantsEscherichia coliPharmacologyLeukemiaPlants MedicinalbiologyTraditional medicineved/biologyPlant ExtractsProvidencia stuartiiOrganic ChemistryResazurinbiology.organism_classificationAntineoplastic Agents PhytogenicAnti-Bacterial AgentsFerulaComplementary and alternative medicinechemistryDrug Resistance NeoplasmMolecular MedicineEgyptFemaleAntibacterial activitySesquiterpenesFerula hermonisPhytotherapyPlanta medica
researchProduct

Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus

2019

Background. Management of venous thromboembolism (VTE) in patients with haematologic malignancies and thrombocytopenia is clinically challenging due to the related risks. No prospective studies or clinical trials have been carried out and, therefore, no solid evidence on this compelling issue is available. Methods. Given this, an expert panel endorsed by the Gruppo Italiano Malattie Ematologiche dell'Adulto Working Party on Thrombosis and Haemostasis was set up to produce a formal consensus, according to the RAND method, in order to issue clinical recommendations about the platelet (PLT) cut-off for safe administration of low molecular weight heparin (LMWH) in thrombocytopenic (PLT <100×…

venous thrombosis thrombocytopenia blood cancer anticoagulant treatment consensusanticoagulantsblood cancerblood plateletsvenous thromboembolismthrombocytopeniaHeparin Low-Molecular-Weightheparinplatelet countanticoagulant treatmentSettore MED/15 - MALATTIE DEL SANGUEVenous thromboembolism haematological malignancythrombocytopeniaconsensuslow-molecular-weightOriginal Articlehematologic neoplasmscardiovascular diseasesvenous thrombosishumansanticoagulant treatment; blood cancer; consensus; thrombocytopenia; venous thrombosis; anticoagulants; blood platelets; heparin low-molecular-weight; humans; platelet count; consensus; hematologic neoplasms; thrombocytopenia; venous thromboembolismAnticoagulant treatment; Blood cancer; Consensus; Thrombocytopenia; Venous thrombosis
researchProduct

Human Papillomavirus Type 16 E7 Peptide-Directed CD8+ T Cells from Patients with Cervical Cancer Are Cross-Reactive with the Coronavirus NS2 Protein

2003

ABSTRACTHuman papillomavirus type 16 (HPV16) E6 and E7 oncoproteins are required for cellular transformation and represent candidate targets for HPV-specific and major histocompatibility complex class I-restricted CD8+-T-cell responses in patients with cervical cancer. Recent evidence suggests that cross-reactivity represents the inherent nature of the T-cell repertoire. We identified HLA-A2 binding HPV16 E7 variant peptides from human, bacterial, or viral origin which are able to drive CD8+-T-cell responses directed against wild-type HPV16 E7 amino acid 11 to 19/20 (E711-19/20) epitope YMLDLQPET(T) in vitro. CD8+T cells reacting to the HLA-A2-presented peptide from HPV16 E711-19(20)recogni…

virusesPapillomavirus E7 ProteinsImmunologyMolecular Sequence DataPriming (immunology)Epitopes T-LymphocyteUterine Cervical NeoplasmsCD8-Positive T-LymphocytesCross ReactionsViral Nonstructural Proteinsmedicine.disease_causeMajor histocompatibility complexLymphocyte ActivationMicrobiologyEpitopeImmune systemVirologyHLA-A2 AntigenmedicineCytotoxic T cellHumansHuman coronavirus OC43Amino Acid SequencePapillomaviridaeCoronavirusbiologyPapillomavirus Infectionsvirus diseasesOncogene Proteins Viralbiology.organism_classificationVirologyMolecular biologyCoronavirusTumor Virus InfectionsInsect Sciencebiology.proteinPathogenesis and ImmunityFemalePeptidesCD8Journal of Virology
researchProduct

Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus

2010

Apoptosis is a fundamental host defence mechanism against invading microbes. Inactivation of NF-kappaB attenuates encephalomyocarditis virus (EMCV) virulence by triggering rapid apoptosis of infected cells, thereby pre-emptively limiting viral replication. Recent evidence has shown that hypoxia-inducible factor (HIF) increases NF-kappaB-mediated anti-apoptotic response in clear-cell renal cell carcinoma (CCRCC) that commonly exhibit hyperactivation of HIF due to the loss of its principal negative regulator, von Hippel-Lindau (VHL) tumour suppressor protein. Here, we show that EMCV challenge induces a strong NF-kappaB-dependent gene expression profile concomitant with a lack of interferon-me…

virusesTransplantation HeterologousApoptosisMice SCIDBiologyNF-κBMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRNA interferenceCell Line TumorVHLEMCVBasic Helix-Loop-Helix Transcription FactorsAnimalsHIFEncephalomyocarditis virusRNA Small InterferingCarcinoma Renal CellResearch Articles030304 developmental biology0303 health sciencesNF-kappa BNF-κBNFKB1RCCVirologyKidney Neoplasms3. Good healthOncolytic virusOncolytic VirusesViral replicationchemistryVon Hippel-Lindau Tumor Suppressor ProteinApoptosisCell culture030220 oncology & carcinogenesisCancer researchMolecular MedicineRNA InterferenceSignal transductionSignal TransductionEMBO Molecular Medicine
researchProduct

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled…

2013

Obesity is an unfavorable prognostic factor in breast cancer (BC) patients regardless of menopausal status and treatment received. However, the association between obesity and survival outcome by pathological subtype requires further clarification. METHODS: We performed a retrospective analysis including 5,683 operable BC patients enrolled in four randomized clinical trials (GEICAM/9906, GEICAM/9805, GEICAM/2003-02, and BCIRG 001) evaluating anthracyclines and taxanes as adjuvant treatments. Our primary aim was to assess the prognostic effect of body mass index (BMI) on disease recurrence, breast cancer mortality (BCM), and overall mortality (OM). A secondary aim was to detect differences o…

Índice de Masa CorporalOncologyReceptor ErbB-2medicine.medical_treatmentObesidad:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis [Medical Subject Headings]Supervivencia sin EnfermedadBody Mass IndexAntineoplastic Combined Chemotherapy ProtocolsMedicineAnthracyclinesYoung adultMedicine(all)Hazard ratioNeoplasias de la MamaPronósticoFemeninoMiddle AgedPrognosisChemotherapy regimenTreatment OutcomeFemaleTaxoidsMastectomyResearch ArticleAdultmedicine.medical_specialtyAnálisis de Supervivencia:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Mass Index [Medical Subject Headings]Breast NeoplasmsDisease-Free SurvivalYoung AdultBreast cancerInternal medicineAdjuvant therapyHumansObesity:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Disease-Free Survival [Medical Subject Headings]:Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings]AgedGynecologyDose-Response Relationship Drugbusiness.industry:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [Medical Subject Headings]Retrospective cohort studyAntineoplásicosmedicine.disease:Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings]:Check Tags::Female [Medical Subject Headings]Multivariate Analysis:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings]Neoplasm Recurrence LocalbusinessBody mass index
researchProduct

Management of Patients with Gastric or Gastroesophageal Junction Cancer: From Theory to Integrated Clinical Path- ways Implementation in the Real Wor…

2022

Introduction: Best care of esophagogastric junction and gastric cancer (EGC) requires a complex, timely interaction between members of a multi-disciplinary team (MDT). An integrated clinical pathway (ICP) is necessary to achieve this goal as well as the implementation of its use in daily practice. The objective of this study was to elaborate on an integrated clinical pathway for the multi-disciplinary management of ECG. Authors also put in act an implementation program to improve adherence to guidelines thought an ICP. Method: This prospective work carried out by a multi-institutional MDT in Italy identified expert panel extracted relevant recommendations and/or statements from published pa…

flowchart.Italyesophagogastric junction cancerStomach Neoplasmsgastric cancerCritical PathwaysHumansclinical pathwayEsophagogastric JunctionProspective Studiesmultidisciplinary team
researchProduct